AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9678108
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives (all preparations)
Trial: 9678108
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives (desogestrel/ethinylestradiol 150/20)
Trial: 3549413
Drug: Propranolol (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (doses that reduced resting heart rate by 25%)
Trial: 29155195
Drug: CDDU +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDDU + ICI (10 µg alprostadil) repeated assessments (maximum of 3 rounds)
Trial: 29155195
Drug: CDDU +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDDU + ICI (10 µg alprostadil) before and after sexological counseling
Trial: 16930101
Drug: Oral melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral melatonin (3mg)
Trial: 10680790
Drug: 3,4-diaminopyridine (DAP),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3,4-diaminopyridine (DAP), 20 mg three times daily for 6 days
Trial: 9375332
Drug: Inhalation rewarming
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation rewarming with saturated air at approximately 43 degrees C
Trial: 7654578
Drug: Amorolfine spray
RxNorm normalized name: amorolfine
DrugBank: Amorolfine (DB09056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amorolfine spray 0.5%
Trial: 7654578
Drug: Amorolfine spray
RxNorm normalized name: amorolfine
DrugBank: Amorolfine (DB09056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amorolfine spray 2%
Trial: 7654578
Drug: Amorolfine spray
RxNorm normalized name: amorolfine
DrugBank: Amorolfine (DB09056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amorolfine spray (both concentrations)
Trial: 3300174
Drug: Declined pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Declined pump treatment
Trial: 29784057
Drug: Norepinephrine (NE)
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norepinephrine (NE) tapering first
Trial: 29784057
Drug: Vasopressin (AVP)
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vasopressin (AVP) tapering first
Trial: 27211885
Drug: Routine oral
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine oral care with thymol
Trial: 20602016
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg piroxicam‐beta‐cyclodextrin
Trial: 20602016
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg piroxicam‐beta‐cyclodextrin
Trial: 1952847
Drug: Temafloxacin hydrochloride
RxNorm normalized name: temafloxacin hydrochloride
DrugBank: Temafloxacin (DB01405)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temafloxacin hydrochloride (400 mg once a day for 7 days)
Trial: 1952847
Drug: Trimethoprim (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim (160 mg) and sulfamethoxazole (800 mg) (TMP-SMZ) twice daily for 10 days
Trial: 27344987
Drug: Existing therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Existing therapy (self-formulated dexamethasone mouth rinse)
Trial: 21272091
Drug: Silodosin at
RxNorm normalized name: Silodosin
DrugBank: Silodosin (DB06207)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Silodosin at 4 mg twice a day
Trial: 21272091
Drug: Tamsulosin at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin at 0.2 mg once a day
Trial: 21272091
Drug: Naftopidil at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naftopidil at 50 mg once a day
Trial: 16772812
Drug: Amantadine 200
RxNorm normalized name: amantadine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine 200 mg/d
Trial: 29287276
Drug: Noninvasive measures
RxNorm normalized name: MEASLES VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noninvasive measures (e.g., the use of a 'soft room', observation in seclusion)
Trial: 29287276
Drug: Invasive measures
RxNorm normalized name: MEASLES VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive measures (e.g., mechanical restraint, forced medication)
Trial: 29287276
Drug: Forced medication
RxNorm normalized name: benzalkonium chloride Topical Solution [Clean Force]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forced medication and mechanical restraint
Trial: 29287276
Drug: Options for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Options for reducing coercion (e.g., music or exercises)
Trial: 25448515
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of intramuscular 17OHP‐C weekly until 36 weeks
Trial: 20559296
Drug: Naltrexone SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone SR (32 mg/day) + Bupropion SR (360 mg/day) + BMOD (N = 591)
Trial: 20559296
Drug: Naltrexone SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone SR (32 mg/day) + Bupropion SR (360 mg/day) + BMOD (N = 482)
Trial: 20559296
Drug: Naltrexone SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone SR (32 mg/day) + Bupropion SR (360 mg/day) + BMOD (N = 301)
Trial: 20559296
Drug: Naltrexone SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone SR (32 mg/day) + Bupropion SR (360 mg/day) + BMOD
Trial: 10392861
Drug: Poloxamer 188
RxNorm normalized name: POLOXAMER 188
DrugBank: Poloxamer 188 (DB11333)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poloxamer 188 as ancillary therapy to thrombolysis
Trial: 1846784
Drug: Sotalol 320
RxNorm normalized name: sotalol 320 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol 320 mg/24 hr
Trial: 1846784
Drug: Sotalol 640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol 640 mg/24 hr
Trial: 23681677
Drug: Parent-child interaction
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-child interaction therapy (immediate treatment)
Trial: 16821204
Drug: Alendronate (ALN),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (ALN), 10 mg daily for 2 years
Trial: 7734258
Drug: 51W89 (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 51W89 (0.1 mg kg‐1, 2 x ED95)
Trial: 7734258
Drug: Atracurium (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium (0.4 mg kg‐1)
Trial: 2789932
Drug: Yohimbine (14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine (14 mg)
Trial: 4154818
Drug: Fluoride topical
RxNorm normalized name: fluoride topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride topical application twice a year (Group 3)
Trial: 4154818
Drug: Fluoride topical
RxNorm normalized name: fluoride topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride topical application once a year (Group 2)
Trial: 29432772
Drug: Synbiotic supplementation
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synbiotic supplementation (L. acidophilus, L. plantarum, L. fermentum, L. gasseri with fructooligosaccharide for 6 weeks)
Trial: 24417565
Drug: Self-administered checklist
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered checklist
Trial: 23652044
Drug: 45 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg/m2 gambogic acid intravenously from Days 1 to 5 of a 2-week cycle (Group A)
Trial: 23652044
Drug: 45 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg/m2 gambogic acid every other day for a total of five times during a 2-week cycle (Group B)
Trial: 21322147
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg/day) and Fluoxetine (20 mg/day) for 6 months
Trial: 21322147
Drug: Naltrexone and
RxNorm normalized name: Naltrexone and Bupropion Hydrochlorides Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone and Fluoxetine placebo
Trial: 21322147
Drug: Naltrexone placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone placebo and Fluoxetine
Trial: 21322147
Drug: Naltrexone placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone placebo and Fluoxetine placebo
Trial: 16871932
Drug: Topical mitomycin-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical mitomycin-C (MMC) applied at a concentration of 0.5 mg/mL for 4 minutes post-frontal sinusotomy.
Trial: 14696846
Drug: Beta-glucuronidase activity
RxNorm normalized name: Recombinant human beta-glucuronidase
DrugBank: Vestronidase alfa (DB12366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Beta-glucuronidase activity in CSF before treatment
Trial: 15235963
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural infusion of 0.25% bupivacaine at a rate of 2‐5 ml.hr(‐1)
Trial: 15235998
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 0.125% or 0.25% bupivacaine and 0.0025% or 0.005% morphine at a rate of 2‐4 ml.hr(‐1)
Trial: 788570
Drug: Streptomycin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptomycin plus isoniazid plus pyrazinamide twice a week
Trial: 21252501
Drug: Intratympanic injection
RxNorm normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratympanic injection of AM-101
Trial: 17367658
Drug: Aliskiren (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren (all doses)
Trial: 9789646
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of antibiotics
Trial: 7811656
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg intranasal midazolam
Trial: 30803175
Drug: Oral magnesium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral magnesium sulfate solution in split doses (group A, n=178)
Trial: 30803175
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose group (group B, n=190)
Trial: 29327733
Drug: Functional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional therapy of mandibular advancement
Trial: 25400085
Drug: Thrice-daily regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-daily regimen of oral hydrocortisone (OHC)
Trial: 12558913
Drug: CIFN 9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIFN 9 microg daily
Trial: 12558913
Drug: CIFN 9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIFN 9 microg daily plus ribavirin 1000 or 1200 mg daily
Trial: 10736983
Drug: Fluvoxamine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (100 mg/die)
Trial: 1601147
Drug: Gonadotropin-releasing hormone
RxNorm normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadotropin-releasing hormone agonist (GnRH-a) - leuprolide acetate (500 micrograms)
Trial: 6397871
Drug: High-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral anticoagulation with shorter heparin treatment
Trial: 6397871
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral anticoagulation with conventional heparin treatment
Trial: 6397871
Drug: High-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral anticoagulation with shorter heparin treatment (second part of the study)
Trial: 6397871
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral anticoagulation with conventional heparin treatment (second part of the study)
Trial: 31144435
Drug: GLP1RA plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP1RA plus basal insulin
Trial: 28405346
Drug: Basal-bolus insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal-bolus insulin
Trial: 26990766
Drug: AQW051 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AQW051 10 mg
Trial: 26990766
Drug: AQW051 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AQW051 50 mg
Trial: 21253451
Drug: Fluticasone Propionate/Salmeterol
RxNorm normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler 230/42mcg (FSC MDI)
Trial: 17689205
Drug: Concurrent smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent smoking cessation treatment during alcohol treatment
Trial: 17689205
Drug: Delayed smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed smoking cessation treatment (6 months later)
Trial: 15897722
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of d-amphetamine
Trial: 12917721
Drug: Group 1
RxNorm normalized name: Chlamydophila psittaci biogroup 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 (intensive treatment)
Trial: 12917721
Drug: Group 2
RxNorm normalized name: Chlamydophila psittaci biogroup 2 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 (less intensive treatment)
Trial: 10150320
Drug: Single 5-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 5-mg dose of ramipril
Trial: 10150320
Drug: Long-term administration
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term administration of 5 mg of ramipril daily for 6 months
Trial: 2201190
Drug: Mifepristone (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (600 mg per day for 2 days)
Trial: 7003434
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: Shunt removal with systemic antibiotics, external ventricular drainage or intermittent ventricular taps for decompression and antibiotic administration; intravenous and intraventricular antibiotics for a minimum of 7 days.
Trial: 7003434
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: Removal and immediate replacement of the shunt with intrashunt antibiotic therapy; intravenous antibiotics for a minimum of 3 weeks and twice daily intraventricular antibiotics for a minimum of 2 weeks.
Trial: 7003434
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: Antibiotics without removal or replacement of the shunt; intravenous antibiotics for a minimum of 3 weeks and twice daily intraventricular antibiotics for a minimum of 2 weeks.
Trial: 30975954
Drug: 150‐mg oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150‐mg oral pregabalin and 400 mg IV ibuprofen
Trial: 30975954
Drug: 75‐mg oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75‐mg oral pregabalin and 400‐mg IV ibuprofen
Trial: 30975954
Drug: 400‐mg IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400‐mg IV ibuprofen
Trial: 30975954
Drug: oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo and IV placebo
Trial: 30975954
Drug: oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo and 400‐mg IV ibuprofen
Trial: 28231660
Drug: Telbivudine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine treatment during second and third trimesters of pregnancy
Trial: 28231660
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no telbivudine treatment)
Trial: 26297142
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m² followed by cisplatin 75 mg/m² (Arm A)
Trial: 26297142
Drug: Docetaxel +
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel + cisplatin with esomeprazole (ESOM) 80 mg p.o. bid for 3 days (Arm B)
Trial: 26297142
Drug: Docetaxel +
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel + cisplatin with esomeprazole (ESOM) 100 mg p.o. bid for 3 days (Arm C)
Trial: 26297142
Drug: PPI (Proton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI (Proton Pump Inhibitors) vs no PPI
Trial: 26297142
Drug: PPI combination
RxNorm normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI combination in triple negative breast cancer (TNBC)
Trial: 26297142
Drug: PPI combination
RxNorm normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI combination effect on overall survival (OS)
Trial: 23273588
Drug: 1,000 mL/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mL/d fluid restriction
Trial: 22040597
Drug: Sham intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sham intervention (de-tuned ultrasound and de-tuned activator treatment)
Trial: 19148431
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of IV cephazolin in the anesthetic induction (Group C)
Trial: 19148431
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of tinidazole orally, 12 hours before the surgery (Group T)
Trial: 19148431
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of tinidazole orally 12 hours before the surgery and 2g of IV cephazolin in the anesthetic induction (Group C+T)
Trial: 16572441
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with etanercept (25 mg subcutaneously twice weekly) and oral MTX (up to 20 mg weekly)
Trial: 16572441
Drug: Methotrexate (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (up to 20 mg weekly)
Trial: 11138459
Drug: Epirubicin (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin (70 mg/m2) days 1 and 8 every 4 weeks
Trial: 11138459
Drug: Epirubicin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin (60 mg/m2) days 1 and 8 plus cisplatin (100 mg/m2) day 1 every 4 weeks
Trial: 1567032
Drug: Epidural fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural fentanyl 100 micrograms/10 mL
Trial: 1567032
Drug: Normal saline-control
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline-control 10 mL
Trial: 3926067
Drug: 5% acyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% acyclovir cream, applied topically five times a day for five days
Trial: 30509268
Drug: Correct inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correct inhalation technique
Trial: 30509268
Drug: Incorrect inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incorrect inhalation technique
Trial: 24802657
Drug: Lobeglitazone 2
RxNorm normalized name: rosiglitazone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lobeglitazone 2 mg
Trial: 24802657
Drug: Lobeglitazone 4
RxNorm normalized name: rosiglitazone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lobeglitazone 4 mg
Trial: 23158229
Drug: Maternal anthelminthic
RxNorm normalized name: pyrantel
DrugBank: Pyrantel (DB11156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal anthelminthic treatment during pregnancy
Trial: 20926997
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of corticosteroid
Trial: 18514620
Drug: Oral amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amino acid supplements alongside ACE inhibitor therapy
Trial: 18514620
Drug: Placebo alongside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo alongside ACE inhibitor therapy
Trial: 15928545
Drug: Individual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual treatment and group exercise
Trial: 12074417
Drug: Volatile inhalation
RxNorm normalized name: Peppermint volatile oil
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volatile inhalation induction and maintenance (Group 1)
Trial: 12074417
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anaesthesia with propofol and a minimal dose sufentanil (Group 2)
Trial: 12074417
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose midazolam-sufentanil (Group 3)
Trial: 28298024
Drug: Subcutaneous IL-1
RxNorm normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous IL-1 receptor antagonist (IL-1Ra) 100 mg administered twice daily for up to 21 days postictus.
Trial: 24517632
Drug: Low HDL-C
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low HDL-C group (<40 mg/dL)
Trial: 20170522
Drug: LeptiCore formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LeptiCore formula A (low dose)
Trial: 20170522
Drug: LeptiCore formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LeptiCore formula B (high dose)